The FDA's July 2026 decision lets people with early Alzheimer's start lecanemab treatment with a weekly at-home injection instead of beginning with biweekly intravenous (IV) infusions. The FDA's approval notice confirms this is the first at-home starting dose cleared for an Alzheimer's drug, removing the requirement that every patient begin treatment at an infusion center. Leqembi (lecanemab) targets amyloid plaques linked to Alzheimer's disease. The new subcutaneous starting dose, called Leqembi Iqlik, builds on a maintenance-only version the FDA approved in August 2025, and it changes who needs an infusion chair at all, not just how maintenance doses are given.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official guidance from FDA — Use this primary source to verify the official guidance.
- Explore the official data from FDA — Use this primary source to review the underlying data.
Table of Contents
- What the July 2026 Approval Actually Changed
- How the At-Home Injection Compares to IV Dosing
- Why Monitoring Still Matters With the At-Home Option
- Reaction Risks, Cost, and Deciding Between Routes
- Questions to Raise With a Care Team Before Switching
- Frequently Asked Questions
What the July 2026 Approval Actually Changed
Before this decision, every new Leqembi patient had to spend roughly 18 months on biweekly IV infusions before switching to the once-weekly subcutaneous injection for maintenance, according to Eisai and Biogen's August 2025 announcement. The July 2026 approval removes that IV-first requirement, letting eligible patients start on the injection from day one. The approval covers the same population as IV Leqembi: adults with mild cognitive impairment or mild dementia caused by confirmed Alzheimer's pathology, as reported by NeurologyLive.
Nobody gains eligibility they didn't already have under the IV label; the change is in how treatment begins, not who qualifies. IV infusions remain available and are still the standard route for patients who prefer clinical supervision or whose care team recommends it. The decision adds a path, rather than replacing the existing one.
How the At-Home Injection Compares to IV Dosing
The new starting dose is two 250 mg subcutaneous injections, 500 mg total, given once a week in the abdomen, thigh, or upper arm. Each injection takes about 15 seconds. The IV option instead delivers 10 mg/kg over roughly one hour, every two weeks, according to Drug Topics.
That difference reshapes the time commitment around treatment. A weekly injection takes under a minute and can happen at home, while an IV infusion requires a scheduled visit, a seated infusion of about an hour, and travel time on both ends. For a patient without easy transportation, or a caregiver juggling other responsibilities, the injection removes a recurring logistical burden that the infusion does not. The trade-off is that the injection shifts responsibility for correct technique and timing to the patient or caregiver, where the infusion puts a trained clinician in charge of the entire process.
Why Monitoring Still Matters With the At-Home Option
Leqembi carries a boxed warning for amyloid-related imaging abnormalities, or ARIA — swelling or bleeding in the brain that shows up on MRI scans. That warning applies equally to the subcutaneous injection and the IV infusion, and the label recommends ApoE ε4 genotype testing before starting treatment because people with two copies of that gene variant face a higher rate of symptomatic or severe ARIA, per the FDA's prescribing information. The monitoring schedule doesn't relax for home dosing. The label calls for an MRI roughly one week before the 3rd, 5th, 7th, and 14th doses, along with close attention to ARIA symptoms during the first 14 weeks of treatment, regardless of which route a patient uses, according to an FDA bulletin on the prescribing information.
Those symptoms include confusion, headache, vision changes, and seizures. What changes is who is watching between those scheduled MRI visits. An infusion center provides staffed observation during and shortly after each IV dose. At-home dosing removes that on-site supervision, so the FDA's approval announcement places the burden of watching for ARIA symptoms on patients and caregivers during the days between doses and scans, rather than during a supervised visit.
Reaction Risks, Cost, and Deciding Between Routes
Reaction patterns differ by route. In a company sub-study of 49 patients who had completed at least 18 months of IV therapy before switching to the weekly injection, systemic reactions — reactions affecting the whole body, such as fever or chills — occurred in under 1% of injection recipients, compared with roughly 26% of IV recipients, according to Eisai and Biogen's investor release. That gap is the main safety argument for the injection. The injection trades that lower systemic-reaction rate for a different risk: localized reactions at the injection site, including redness, swelling, rash, pain, and bruising.
Some reports describe severe site reactions serious enough that patients stopped using the autoinjector, per MedTech Spectrum. Cost also diverges. Reported list pricing puts the subcutaneous maintenance regimen at about $19,500 a year, above the roughly $13,300 annual wholesale price reported for IV maintenance dosing, according to FiercePharma. A patient or family comparing routes should weigh that price difference alongside insurance coverage, since the two regimens are not priced the same even though they deliver the same drug.
Questions to Raise With a Care Team Before Switching
Someone considering the at-home starting dose, or a switch from IV to injection, has specific questions worth bringing to a neurologist or memory care specialist: A care team can walk through each of these before the first dose, so the decision between an at-home injection and a clinic-based infusion rests on a patient's specific genotype, support system, and tolerance for localized reactions rather than on convenience alone.
- Has ApoE ε4 genotype testing been done, and what does the result mean for ARIA risk on this specific route?
- Who reviews MRI results between the scheduled scans before the 3rd, 5th, 7th, and 14th doses, and how quickly?
- What ARIA symptoms should a caregiver treat as an emergency rather than something to mention at the next visit?
- Does insurance cover the subcutaneous regimen at the same level as the IV regimen, given the reported price difference?
- Is there a backup plan if an injection-site reaction becomes severe enough to require stopping the autoinjector?
Frequently Asked Questions
Does the at-home injection replace IV infusions entirely?
No. IV infusions remain available; the July 2026 approval adds a subcutaneous starting-dose option rather than eliminating the IV route, per the FDA's approval notice.
Does switching to the injection remove the need for MRI monitoring?
No. The same MRI schedule before the 3rd, 5th, 7th, and 14th doses applies to both routes, according to the FDA's prescribing information.
Is the at-home injection safer than the IV infusion?
It carries a much lower rate of systemic reactions (under 1% versus roughly 26% in a company sub-study) but a higher risk of localized injection-site reactions, some severe enough to stop treatment.
You Might Also Like
- FDA’s 2026 At-Home Leqembi IQLIK Starting Dose: Safety and Monitoring Questions for People With Early Alzheimer’s
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: What Changed and What Comes Next for People With Mild Cognitive Impairment
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: What Changed and What Comes Next for People With Mild Cognitive Impairment
